Why Shares of Oncothyreon Imploded Yesterday
Dec 20th 2012 5:14PM
Updated Dec 20th 2012 5:22PM
Shares of biotech company Oncothyreon fell more than 50% yesterday. The company released Phase 3 data for its drug Stimuvax, an experimental vaccine that treats non-small cell lung cancer, which showed that the drug failed to improve overall survival for patients in the clinical trial. In this video, Motley Fool health-care analysts Max Macaluso and Brenton Flynn take us through the details.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report, "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Why Shares of Oncothyreon Imploded Yesterday originally appeared on Fool.com.Brenton Flynn has no positions in the stocks mentioned above. Max Macaluso, Ph.D. has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.